GeneFerm Biotechnology Co Ltd (1796) — Capital Reinvestment Ratio
GeneFerm Biotechnology Co Ltd (1796) has a Capital Reinvestment Ratio of 4.13x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$1.45 Million) in capital expenditures (NT$5.98 Million). Check tangible equity quality of GeneFerm Biotechnology Co Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GeneFerm Biotechnology Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks GeneFerm Biotechnology Co Ltd's Capital Reinvestment Ratio across 8 annual periods. For the full cash flow conversion analysis, see 1796 cash flow metrics.
Annual Capital Reinvestment Ratio for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for GeneFerm Biotechnology Co Ltd from 2017 to 2024. See GeneFerm Biotechnology Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.81x | NT$8.09 Million | NT$22.70 Million | ▲ +647.8% |
| 2023 | 0.38x | NT$190.31 Million | NT$71.40 Million | ▼ -83.5% |
| 2022 | 2.27x | NT$122.43 Million | NT$278.42 Million | ▲ +75.3% |
| 2021 | 1.30x | NT$112.23 Million | NT$145.61 Million | ▼ -11.1% |
| 2020 | 1.46x | NT$56.42 Million | NT$82.32 Million | ▼ -60.7% |
| 2019 | 3.72x | NT$14.69 Million | NT$54.57 Million | ▲ +443.5% |
| 2018 | 0.68x | NT$42.14 Million | NT$28.81 Million | ▼ -24.3% |
| 2017 | 0.90x | NT$61.08 Million | NT$55.16 Million | — |